Okitask (Ketoprofen Lysine)

Ketoprofen lysine works by inhibiting the cyclo‑oxygenase enzymes COX‑1 and COX‑2, which reduces the formation of prostaglandins—key mediators of inflammation, pain and fever. Lower prostaglandin levels decrease vascular permeability, edema and nociceptor activation, providing anti‑inflammatory and analgesic effects.

The specific dose of Okitask is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, age, renal and hepatic function, and concomitant medications. Healthcare professionals tailor the regimen to achieve optimal pain control while minimizing risk.

Ketoprofen lysine, like other NSAIDs, is generally avoided during the third trimester of pregnancy because it may affect fetal cardiovascular function. Use during early pregnancy or while breastfeeding should only be considered if the potential benefit outweighs the risk, and after consultation with a qualified healthcare provider.

To request Okitask, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Okitask (ketoprofen lysine) offers potent anti‑inflammatory and analgesic activity comparable to other NSAIDs such as ibuprofen or diclofenac, but its lysine salt formulation may provide faster absorption and onset of action. Choice of NSAID depends on individual patient risk factors, tolerability, and specific clinical scenarios.

Okitask tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keeping the product in a dry, cool place helps maintain its stability and potency throughout its shelf life.

Okitask is supplied as oral tablets and is taken by mouth with a full glass of water. It can be taken with or without food, although taking it with food may reduce gastrointestinal discomfort. Patients should follow the dosing instructions provided by their prescriber.

Serious risks include gastrointestinal bleeding or ulceration, severe skin reactions such as Stevens‑Johnson syndrome, renal impairment, hepatotoxicity, and anaphylactic reactions. Patients should be monitored for signs of bleeding, rash, changes in urine output, or liver dysfunction, and seek immediate medical attention if these occur.

Okitask is contraindicated in patients with known hypersensitivity to ketoprofen or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe heart failure, and in the third trimester of pregnancy. Caution is also advised for individuals with significant renal or hepatic impairment.